NASDAQ:ESPR - Esperion Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $49.27
Forecasted Upside: 215.85 %
Number of Analysts: 10
Breakdown:
2 Sell Ratings
5 Hold Ratings
2 Buy Ratings
1 Strong Buy Ratings

^$15.60 As of 07/23/2021 01:00 AM ET

▼ -1.19 (-7.09%)

1 month | 3 months | 12 months

Get New Esperion Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ESPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESPR

^$49.27

▲ +215.85% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $49.27, with a high forecast of $134.00 and a low forecast of $20.00. The average price target represents a 215.85% upside from the last price of $15.60.

Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in Esperion Therapeutics. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

2/1/2020

1 strong buy ratings
5 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

5/1/2020

1 strong buy ratings
5 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

7/30/2020

1 strong buy ratings
5 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/28/2020

1 strong buy ratings
5 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

1/26/2021

1 strong buy ratings
2 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

4/26/2021

1 strong buy ratings
2 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

6/25/2021

1 strong buy ratings
2 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/11/2021	Stifel Nicolaus	Reiterated Rating	Buy ➝ Hold	$37.00 ➝ $20.00	Low
5/5/2021	BTIG Research	Lower Price Target		$90.00 ➝ $71.00	High
5/5/2021	Northland Securities	Lower Price Target	Market Perform	$30.00 ➝ $24.00	High
5/5/2021	Credit Suisse Group	Lower Price Target	Outperform	$45.00 ➝ $36.00	High
5/5/2021	Morgan Stanley	Lower Price Target	Equal Weight	$30.00 ➝ $22.00	High
5/5/2021	JMP Securities	Lower Price Target	Market Outperform	$191.00 ➝ $111.00	High
5/5/2021	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$37.00 ➝ $20.00	High
3/11/2021	Morgan Stanley	Initiated Coverage	Equal Weight	$30.00	Medium
2/25/2021	Needham & Company LLC	Lower Price Target	Strong-Buy	$150.00 ➝ $134.00	High
2/12/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$40.00 ➝ $30.00	Low
2/9/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$44.00 ➝ $24.00	Low
1/15/2021	Bank of America	Downgrade	Buy ➝ Neutral	$52.00 ➝ $35.00	High
11/10/2020	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$45.00	Medium
10/15/2020	Bank of America	Lower Price Target	Buy	$55.00 ➝ $52.00	Low
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Sell	$35.00	Low
8/17/2020	Bank of America	Lower Price Target	Buy	$60.00 ➝ $55.00	Low
8/11/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High
8/10/2020	Stifel Nicolaus	Reiterated Rating	Buy	$75.00	High
8/10/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$83.00 ➝ $45.00	High
6/29/2020	Credit Suisse Group	Initiated Coverage	Buy	$83.00	High
6/26/2020	Stifel Nicolaus	Reiterated Rating	Buy	$75.00	High
6/23/2020	Northland Securities	Initiated Coverage	Hold	$42.00	High
6/9/2020	Credit Suisse Group	Reiterated Rating	Buy	$87.00	Medium
5/7/2020	Jefferies Financial Group	Lower Price Target	Buy	$85.00 ➝ $70.00	High
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High
5/7/2020	Northland Securities	Reiterated Rating	Hold	$42.00	High
5/7/2020	Citigroup	Boost Price Target	Buy	$46.00 ➝ $56.00	High
5/6/2020	Stifel Nicolaus	Reiterated Rating	Buy	$76.00	High
4/20/2020	Stifel Nicolaus	Reiterated Rating	Buy		Low
4/20/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	Low
4/16/2020	Northland Securities	Lower Price Target	Market Perform	$60.00 ➝ $42.00	High
4/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High
4/1/2020	Bank of America	Initiated Coverage	Buy	$50.00	High
3/31/2020	Needham & Company LLC	Reiterated Rating	Buy	$158.00	High
3/17/2020	Citigroup	Upgrade	Neutral ➝ Buy		High
2/28/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$46.00 ➝ $47.00	Low
2/27/2020	Cowen	Reiterated Rating	Buy	$87.00	Medium
2/24/2020	Needham & Company LLC	Boost Price Target	Strong-Buy	$144.00 ➝ $158.00	Medium
2/24/2020	JMP Securities	Reiterated Rating	Outperform	$191.00	Medium
2/23/2020	Stifel Nicolaus	Reiterated Rating	Buy	$83.00	Medium
2/23/2020	Northland Securities	Downgrade	Outperform ➝ Market Perform	$60.00	Medium
2/19/2020	BTIG Research	Reiterated Rating	Buy	$90.00	Medium
2/14/2020	Citigroup	Downgrade	Buy ➝ Neutral	$73.00 ➝ $82.00	High
1/31/2020	Chardan Capital	Reiterated Rating	Hold	$65.00	High
11/6/2019	Cowen	Reiterated Rating	Buy		Low
9/17/2019	Stifel Nicolaus	Lower Price Target	Buy	$112.00 ➝ $70.00	Low
9/16/2019	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$55.00 ➝ $45.00	Medium
8/29/2019	Northland Securities	Reiterated Rating	Buy		High
8/8/2019	Northland Securities	Reiterated Rating	Buy		Medium
7/18/2019	Cowen	Reiterated Rating	Buy	$80.00	Low
6/14/2019	Northland Securities	Set Price Target	Buy	$65.00	Medium
6/13/2019	Stifel Nicolaus	Reiterated Rating	Buy		Low
6/13/2019	Cowen	Reiterated Rating	Buy	$85.00	Medium
5/29/2019	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$50.00	Medium
5/28/2019	Citigroup	Set Price Target	Buy	$73.00	High
5/6/2019	Credit Suisse Group	Boost Price Target	Outperform	$79.00 ➝ $90.00	Medium
5/6/2019	Bank of America	Upgrade	Underperform ➝ Neutral		Low
5/5/2019	Cowen	Set Price Target	Buy	$94.00	High
4/26/2019	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$50.00	Low
4/2/2019	Northland Securities	Set Price Target	Buy	$65.00	Low
3/29/2019	Stifel Nicolaus	Reiterated Rating	Buy	$112.00	Low
3/14/2019	Chardan Capital	Reiterated Rating	Hold	$50.00	Medium
3/13/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$38.00 ➝ $47.00	High
3/1/2019	Northland Securities	Reiterated Rating	Buy	$65.00	Low
1/15/2019	Cowen	Reiterated Rating	Buy	$94.00	Low
1/7/2019	Needham & Company LLC	Boost Price Target	Strong-Buy	$94.00 ➝ $114.00	Low
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$45.00	High
12/10/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$89.00 ➝ $104.00	Medium
10/29/2018	Northland Securities	Upgrade	Market Perform ➝ Outperform	$65.00	High
10/26/2018	Cowen	Set Price Target	Buy	$82.00	Low
10/16/2018	BTIG Research	Initiated Coverage	Buy ➝ Buy	$82.00	High
9/14/2018	Stifel Nicolaus	Initiated Coverage	Buy	$89.00	High
8/17/2018	Citigroup	Upgrade	Neutral ➝ Buy	$57.00 ➝ $75.00	Low
8/6/2018	Cowen	Reiterated Rating	Buy	$95.00	Low
7/20/2018	Chardan Capital	Upgrade	Hold	$32.50	Low
7/11/2018	Northland Securities	Downgrade	Outperform ➝ Market Perform		Medium
5/16/2018	UBS Group	Set Price Target	Buy	$90.00 ➝ $75.00	Low
5/4/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$108.00 ➝ $73.00	N/A
5/3/2018	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$100.54 ➝ $41.00	High
5/3/2018	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy ➝ Buy	$100.00 ➝ $75.00	High
5/2/2018	Bank of America	Reiterated Rating	Buy ➝ Underperform		High
4/19/2018	Northland Securities	Boost Price Target	Buy	$100.00 ➝ $121.00	Low
3/27/2018	Chardan Capital	Boost Price Target	Neutral ➝ Neutral	$75.00 ➝ $100.00	Low
3/9/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$100.00	Low
3/8/2018	JMP Securities	Boost Price Target	Outperform	$60.00 ➝ $153.00	High
3/7/2018	Stifel Nicolaus	Set Price Target	Buy	$105.00	High
2/21/2018	UBS Group	Set Price Target	Neutral ➝ Neutral	$88.00 ➝ $90.00	High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $65.00	High
2/21/2018	Needham & Company LLC	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$81.00 ➝ $94.00	Low
1/22/2018	Citigroup	Downgrade	Buy ➝ Neutral	$77.00 ➝ $96.00	Low
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$103.00	Low
1/17/2018	UBS Group	Set Price Target	Buy ➝ Buy	$62.00 ➝ $88.00	High
1/15/2018	Stifel Nicolaus	Set Price Target	Positive ➝ Buy	$70.00 ➝ $105.00	Medium
1/5/2018	Bank of America	Upgrade	Neutral ➝ Buy	$76.00	High
12/14/2017	Needham & Company LLC	Upgrade	Buy ➝ Strong-Buy	$72.00 ➝ $81.00	Medium
12/6/2017	Chardan Capital	Boost Price Target	Neutral	$20.00 ➝ $75.00	High
12/5/2017	Chardan Capital	Reiterated Rating	Neutral ➝ Neutral	$20.00 ➝ $75.00	High
11/10/2017	Northland Securities	Reiterated Rating	Buy	$72.00	N/A
10/4/2017	Stifel Nicolaus	Reiterated Rating	Buy	$70.00	Medium
10/4/2017	Northland Securities	Reiterated Rating	Buy	$72.00	Medium
9/7/2017	Cowen	Initiated Coverage	Outperform	$64.00	Low
8/29/2017	Northland Securities	Initiated Coverage	Outperform ➝ Outperform	$72.00	Medium
8/21/2017	Jefferies Financial Group	Reiterated Rating	Buy	$85.00	Low
8/11/2017	Bank of America	Reiterated Rating	Neutral ➝ Neutral	$60.00	Medium
8/10/2017	Stifel Nicolaus	Reiterated Rating	Buy	$60.00 ➝ $70.00	High
8/9/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$48.00 ➝ $64.00	High
8/8/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$85.00 ➝ $55.00	Low
8/8/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Positive	$58.00 ➝ $72.00	High
7/10/2017	Jefferies Financial Group	Initiated Coverage	Hold ➝ Hold	$55.00	Low
6/27/2017	UBS Group	Reiterated Rating	Buy	$52.00 ➝ $57.00	N/A
6/26/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $60.00	Low
6/23/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$48.00	High
6/22/2017	Citigroup	Reiterated Rating	Buy		High
3/29/2017	UBS Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $52.00	N/A
3/21/2017	Citigroup	Boost Price Target		$77.00	High
3/21/2017	JPMorgan Chase & Co.	Boost Price Target		$22.00 ➝ $50.00	High
3/20/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold	$22.00 ➝ $50.00	Medium
3/20/2017	Citigroup	Set Price Target	Buy	$39.00	Medium
3/20/2017	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High
3/20/2017	Needham & Company LLC	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $58.00	High
3/20/2017	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$29.00	High
3/18/2017	Needham & Company LLC	Set Price Target	Buy	$25.00	High
3/13/2017	Citigroup	Set Price Target	Buy	$39.00	Low
2/28/2017	Citigroup	Upgrade	Neutral ➝ Buy	$14.00 ➝ $39.00	N/A
2/23/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$20.00 ➝ $30.00	N/A
2/16/2017	UBS Group	Boost Price Target	Neutral	$11.00 ➝ $23.00	N/A
2/7/2017	Royal Bank of Canada	Set Price Target	Hold	$20.00	N/A
2/4/2017	Needham & Company LLC	Set Price Target	Buy	$25.00	N/A
1/10/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	N/A
1/3/2017	Royal Bank of Canada	Reiterated Rating	Hold	$15.00	N/A
12/20/2016	Credit Suisse Group	Reiterated Rating	Sell	$12.00	N/A
11/14/2016	Citigroup	Downgrade	Buy ➝ Neutral		N/A
11/6/2016	JMP Securities	Reiterated Rating	Buy		N/A
10/15/2016	Stifel Nicolaus	Reiterated Rating	Buy	$64.00 ➝ $30.00	N/A
10/15/2016	Chardan Capital	Reiterated Rating	Neutral	$12.50	N/A
10/14/2016	Credit Suisse Group	Boost Price Target	Underperform	$10.00 ➝ $14.00	N/A
10/13/2016	Chardan Capital	Set Price Target	Hold	$13.00	N/A
9/22/2016	Stifel Nicolaus	Reiterated Rating	Buy	$64.00	N/A
8/31/2016	Barclays	Set Price Target	Hold	$13.00	N/A
8/5/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$15.00	N/A

(Data available from 7/25/2016 forward)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Today's Range

Now: $15.60

$15.55

$17.00

50 Day Range

MA: $20.94

$15.60

$26.37

52 Week Range

Now: $15.60

$15.55

$43.74

Volume

836,528 shs

Average Volume

536,132 shs

Market Capitalization

$439.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Esperion Therapeutics?

The following Wall Street research analysts have issued stock ratings on Esperion Therapeutics in the last year: Bank of America Co., BTIG Research, Credit Suisse Group AG, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Northland Securities, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ESPR.

What is the current price target for Esperion Therapeutics?

11 Wall Street analysts have set twelve-month price targets for Esperion Therapeutics in the last year. Their average twelve-month price target is $49.27, suggesting a possible upside of 215.9%. Needham & Company LLC has the highest price target set, predicting ESPR will reach $134.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $20.00 for Esperion Therapeutics in the next year.
View the latest price targets for ESPR.

What is the current consensus analyst rating for Esperion Therapeutics?

Esperion Therapeutics currently has 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESPR, but not buy more shares or sell existing shares.
View the latest ratings for ESPR.

What other companies compete with Esperion Therapeutics?

Other companies that are similar to Esperion Therapeutics include Harmony Biosciences, Zymeworks, PMV Pharmaceuticals, NGM Biopharmaceuticals, Constellation Pharmaceuticals, Prelude Therapeutics, Amarin, Avid Bioservices, MacroGenics, Y-mAbs Therapeutics, Indivior, Connect Biopharma, ADC Therapeutics, COMPASS Pathways and Madrigal Pharmaceuticals.

How do I contact Esperion Therapeutics' investor relations team?

Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com.